Aarti Drugs Ltd
Aarti Drugs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #52 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27. Aarti Drugs anticipates a new growth phase as strategic investments begin aligning, with more significant financial impact expected in upcoming quarters due to increased capacity utilization and improved product mix.
From Aarti Drugs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27.
- Expected volume growth of 12% to 15% in FY '27 driven mainly by new projects (salicylic acid and Sayakha amines).
- Existing product basket projected to deliver single-digit volume growth.
- Formulations, especially oncology and exports, expected to grow, with formulations playing a larger role in future revenue.
- Ramp-up of Sayakha plant utilization expected from 30% to 50% by March/April 2026, reaching 75% thereafter, supporting volume growth.
2 more points from Aarti Drugs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR 150-200 crores annual capex expected for next 2 years, covering new projects and maintenance.
- Investments include oncology dossier development, formulation expansion, and brownfield expansions.
- Greenfield projects nearing completion; ramp-up expected within 6-24 months for Sayakha and salicylic acid plants.
- Plans to expand metformin facility to 2,500-3,000 tons/month (currently 1,450-1,500 tons), including US FDA approvals and potential ANDA launch via Pinnacle.
- Capacity expansion for cardiovascular and antifungal products.
- Exploring CDMO opportunities in chlorosulfonation chemistry and methylamine derivatives.
2 more points from Aarti Drugs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Aarti Drugs Ltd said on order book & pipeline — free account, 30 seconds.
Aarti Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Guj. Themis Bio. (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Drugs Ltd Q3 FY26 results?
FY '26 growth was below expectations; volume growth of 15% in H2 is pushed into FY '27. Aarti Drugs anticipates a new growth phase as strategic investments begin aligning, with more significant financial impact expected in upcoming quarters due to increased capacity utilization and improved product mix.
What is Aarti Drugs Ltd share price analysis?
Aarti Drugs Ltd currently shows a neutral. The stock trades at a P/E of 19.7 with a market cap of ₹3,800 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs Ltd planning capital expenditure?
INR 150-200 crores annual capex expected for next 2 years, covering new projects and maintenance.
Keep Aarti Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.